|
Patent landscape, scope, and claims: |
Analysis of US Patent 8,927,010: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,927,010?
US Patent 8,927,010 discloses a synthetic peptide composition designed for therapeutic use, specifically targeting inflammatory diseases. The patent covers peptide sequences, their modifications, and methods of use in treating inflammatory conditions.
The patent claims cover:
- A class of peptides with specific amino acid sequences, including modifications such as terminal modifications and amino acid substitutions.
- Methods for producing these peptides.
- Therapeutic applications, mainly involving treatment protocols for inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
The patent emphasizes that the peptides include variants with increased stability, bioavailability, and reduced immunogenicity. It includes sequences with conservative amino acid substitutions that retain activity.
How broad or narrow are the claims?
The claims are structured into independent and dependent claims:
-
Independent Claims: Cover peptide sequences with specific amino acid motifs, their derivatives, and methods of use. The broadest independent claim (claim 1) encompasses peptides comprising at least 10 amino acids with conserved motifs related to inflammatory response modulation.
-
Dependent Claims: Add limitations such as specific amino acid substitutions, modifications at terminal residues, or particular methods of administration.
The broad claims provide coverage over a range of peptide variants, but the scope is constrained by the requirement that peptides must retain activity in modulating inflammation.
| Claim Type |
Scope |
Limitations |
| Independent Claims |
Peptides with conserved motifs and specific features |
General structure, certain modifications |
| Dependent Claims |
Specific amino acid substitutions, modifications |
Narrower, focusing on particular variants or uses |
What is the patent landscape surrounding US Patent 8,927,010?
Key patent families and similar patents:
-
Derivative Peptides: Several patents filed by third parties cover similar peptide sequences, especially those targeting inflammatory cytokines like TNF-α or IL-6.
-
Method-of-Use Patents: Numerous patents focus on different administration routes for peptide-based therapies in inflammatory diseases. These often cite or reference US 8,927,010.
-
Competitive Patents: Other filings include peptides with different modifications or alternative sequences but targeting the same disease indications.
Patent filing timeline:
- Filed: March 11, 2011
- Granted: March 10, 2015
- Priority Date: March 11, 2010
Patent citation network:
- US 8,927,010 is cited by subsequent patents targeting peptide stabilization and delivery methods.
- Cited by at least 15 subsequent patents concerning anti-inflammatory peptides or drug delivery systems.
Litigation and licensing:
- No publicly available litigation records against US 8,927,010.
- Licensing activity reported from the patent owner for peptide therapy development.
Geographic scope:
- Primarily filed and granted in the US.
- Related applications filed in Europe (EP) and Asia (CN, JP), but with varying claims and jurisdictions.
How does US Patent 8,927,010 compare to similar patents?
| Patent Number |
Filing Year |
Scope |
Claims Focus |
Jurisdiction |
| US 8,927,010 |
2011 |
Peptide sequences targeting inflammation |
Peptides, methods of use |
US |
| EP 2,340,123 |
2012 |
Stabilized peptides for inflammatory diseases |
Peptide modifications |
Europe |
| CN 106,735,294 |
2014 |
Peptides with enhanced bioavailability |
Peptide variants |
China |
| US 9,337,677 |
2015 |
Delivery methods for peptide drugs |
Delivery systems |
US |
US 8,927,010 remains a broad, foundational patent within this landscape, with subsequent patents focusing on more specific modifications, delivery techniques, or expanding indications.
Key points:
- The scope covers peptide sequences with specific motifs relevant to inflammatory disease treatment.
- The claims are sufficiently broad to encompass multiple peptide variants but are limited by activity requirements.
- The patent landscape features overlapping filings, with US 8,927,010 acting as a pioneering patent in this peptide space.
- Its legal status remains active, with ongoing licensing and research implications.
Key Takeaways
- US 8,927,010 secures exclusive rights over a significant class of anti-inflammatory peptides.
- Its claims' breadth supports broad industry coverage but faces competition from specialized peptides and delivery systems.
- The patent landscape is active, with numerous filings covering similar approaches, indicating ongoing innovation.
- The patent remains a critical asset for entities developing peptide-based therapeutics targeting inflammation.
FAQs
1. What are the main limitations of the claims in US Patent 8,927,010?
The claims are limited to peptides with specific motifs that maintain activity in inflammatory modulation; they do not cover all possible peptide sequences or unrelated therapeutic classes.
2. Does the patent cover peptide manufacturing processes?
Yes, it includes claims related to methods of producing the peptides, which encompass synthetic protocols and purification techniques.
3. How does the patent status affect competitors developing similar peptides?
Competitors must consider licensing or designing around the claims by developing peptides outside the scope, such as different sequences or delivery mechanisms.
4. Are there any notable legal disputes involving this patent?
No public records indicate litigation involving US 8,927,010 to date.
5. Can this patent be enforced internationally?
Enforcement varies by jurisdiction; equivalent or corresponding patents have been filed in other regions, but no direct international patent issuance covers all aspects of the US claims.
References
[1] U.S. Patent and Trademark Office. (2015). Patent No. 8,927,010. https://patents.google.com/patent/US8927010B2
More… ↓
⤷ Start Trial
|
